No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group
Table 2
Kaplan-Meier and log-rank test analyses of overall survival and relapse-free survival in patients treated with GO in the consolidation phase.
(a)
Overall survival
rs12459419 genotypes
Genetic risk (ELN 2010)
N
Median (95% CI)
CC
Global
32
2.7 y (1.0-4.3)
0.9
Favorable risk
15
4.7 y (NC)
0.9
Intermediate risk
11
2.5 y (1.6-3.5)
0.9
Adverse risk
4
0.8 y (NC-3.0)
0.8
CT/TT
Global
38
4.4 y (0.5-8.2)
0.9
Favorable risk
13
8.6 y (1.4-15.4)
0.9
Intermediate risk
16
1.7 y (NC-7.8)
0.9
Adverse risk
5
0.1 y (0.4-0.9)
0.8
(b)
Relapse-free survival
rs12459419 genotypes
Genetic risk (ELN 2010)
N
Median (95% CI)
CC
Global
32
1.5 y (1.1-1.9)
0.5
Favorable risk
15
1.7 y (1.3-2.7)
0.6
Intermediate risk
11
1.4 y (1.3-1.6)
0.6
Adverse risk
4
0.2 y (NC-1.2)
0.4
CT/TT
Global
38
1.7 y (0.7-2.6)
0.5
Favorable risk
13
2.7 y (NC-7.5)
0.6
Intermediate risk
16
1.6 y (NC-9.4)
0.6
Adverse risk
5
0.6 y (0.3-0.8)
0.4
Abbreviations: ELN: European Leukemia Net; CI: confidence interval; NC: not calculable.
